Integrative analysis identifies LATS1 as a context-specific regulator of melanoma progression and immune response

Malignant melanoma incidence is increasing, and survival remains poor following metastasis. The main driver oncogenes are BRAF and NRAS. Advancements in targeted agents and immunotherapies have improved survival rates, especially for patients with BRAF mutant melanoma. However, no targeted therapy options are available for patients with NRAS-mutant melanoma. Unfortunately, the development of resistance to all existing therapies remains a challenge. Recent evidence has shown that the MST2/Hippo pathway is deregulated in melanoma. The MST2 pathway core kinase LATS1 is a signalling hub that mediates the crosstalk between cell death and proliferation networks, and its inactivation has been related to melanoma progression and resistance to targeted therapy. However, the mechanisms by which LATS1 influences melanoma biology remain unclear. Here, to investigate this role of LATS1, we developed a lats1 knockout zebrafish melanoma model driven by either BRAF or NRAS mutations. Loss of Lats1 associates with reduced tumour-free survival in BRAF-mutant melanoma and a more invasive phenotype in NRAS-mutant melanoma, confirming a tumour-suppressive function. Integrating transcriptomics and proteomics datasets, we mapped molecular mechanisms mediated by Lats1 in tumours driven by these oncogenes, including pathways associated with the immune response regulated by Lats1. Subsequent validation in patient data confirmed an immune-evasive phenotype, associated with decreased LATS1 expression in BRAF-mutant melanoma. Additionally, the loss of LATS1 in NRAS mutant melanoma patients altered the expression of key DNA damage repair genes. Thus, this study identifies novel pathways controlled by LATS1 in melanoma, which aid in our understanding of the disease and offers new insights to be explored for the development of novel treatment strategies.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-16
DOI
https://doi.org/10.64898/2026.11.12.766289
Primary Topic
Melanoma and MAPK Pathways
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Integrative analysis identifies LATS1 as a context-specific regulator of melanoma progression and immune response

Elena Merino Tejero, Melinda Halász, Elaine O’Boyle, Walter Kölch et al.
1 links
bioRxiv (Cold Spring Harbor Laboratory)
Melanoma and MAPK Pathways
preprint

Integrative analysis identifies LATS1 as a context-specific regulator of melanoma progression and immune response

Elena Merino Tejero, Melinda Halász, Elaine O’Boyle, Walter Kölch, Donagh Egan, Brian Cloak, Andrew P. Badrock, Lucia García-Gutiérrez, David Matallanas, Luis Iglesias Martínez, Pamela Kelly, Adam Hurlstone, Kieran Wynne, Sabina Susanu, Susan Peters, Nourhan Aboud
preprint en

Abstract

Malignant melanoma incidence is increasing, and survival remains poor following metastasis. The main driver oncogenes are BRAF and NRAS. Advancements in targeted agents and immunotherapies have improved survival rates, especially for patients with BRAF mutant melanoma. However, no targeted therapy options are available for patients with NRAS-mutant melanoma. Unfortunately, the development of resistance to all existing therapies remains a challenge. Recent evidence has shown that the MST2/Hippo pathway is deregulated in melanoma. The MST2 pathway core kinase LATS1 is a signalling hub that mediates the crosstalk between cell death and proliferation networks, and its inactivation has been related to melanoma progression and resistance to targeted therapy. However, the mechanisms by which LATS1 influences melanoma biology remain unclear. Here, to investigate this role of LATS1, we developed a lats1 knockout zebrafish melanoma model driven by either BRAF or NRAS mutations. Loss of Lats1 associates with reduced tumour-free survival in BRAF-mutant melanoma and a more invasive phenotype in NRAS-mutant melanoma, confirming a tumour-suppressive function. Integrating transcriptomics and proteomics datasets, we mapped molecular mechanisms mediated by Lats1 in tumours driven by these oncogenes, including pathways associated with the immune response regulated by Lats1. Subsequent validation in patient data confirmed an immune-evasive phenotype, associated with decreased LATS1 expression in BRAF-mutant melanoma. Additionally, the loss of LATS1 in NRAS mutant melanoma patients altered the expression of key DNA damage repair genes. Thus, this study identifies novel pathways controlled by LATS1 in melanoma, which aid in our understanding of the disease and offers new insights to be explored for the development of novel treatment strategies.

bioRxiv (Cold Spring Harbor Laboratory)
University College Dublin (IE), University of Manchester (GB)
Science Foundation Ireland
Good health and well-being
Melanoma and MAPK Pathways
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon